BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 8269588)

  • 41. Cytotoxicity of 2,2':6',2' '-terpyridineplatinum(II) complexes against human ovarian carcinoma.
    Lowe G; Droz AS; Vilaivan T; Weaver GW; Park JJ; Pratt JM; Tweedale L; Kelland LR
    J Med Chem; 1999 Aug; 42(16):3167-74. PubMed ID: 10447962
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The antitumor effect of lobaplatin against Ishikawa endometrial cancer cells in vitro and in vivo.
    He J; Zhang H
    Biomed Pharmacother; 2019 Jun; 114():108762. PubMed ID: 30925454
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antitumor activity of platinum analogs against human lung cancer cell lines and tumor specimens.
    Yonei T; Ohnoshi T; Hiraki S; Ueoka H; Kiura K; Moritaka T; Shibayama T; Tabata M; Segawa Y; Takigawa N
    Acta Med Okayama; 1993 Aug; 47(4):233-41. PubMed ID: 8213217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cycloplatam: a novel platinum compound exhibiting a different spectrum of anti-tumour activity to cisplatin.
    Drees M; Dengler WM; Hendriks HR; Kelland LR; Fiebig HH
    Eur J Cancer; 1995; 31A(3):356-61. PubMed ID: 7786602
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Aphidicolin markedly increases the platinum sensitivity of cells from primary ovarian tumours.
    Sargent JM; Elgie AW; Williamson CJ; Taylor CG
    Br J Cancer; 1996 Dec; 74(11):1730-3. PubMed ID: 8956785
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates.
    Kelland LR; Mistry P; Abel G; Loh SY; O'Neill CF; Murrer BA; Harrap KR
    Cancer Res; 1992 Jul; 52(14):3857-64. PubMed ID: 1617660
    [TBL] [Abstract][Full Text] [Related]  

  • 47. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preparation and characterization of platinum(II) and (IV) complexes of 1,3-diaminepropane and 1,4-diaminebutane: circumvention of cisplatin resistance and DNA interstrand cross-link formation in CH1cisR ovarian tumor cells.
    Alvarez-Valdés A; Pérez JM; López-Solera I; Lannegrand R; Continente JM; Amo-Ochoa P; Camazón MJ; Solans X; Font-Bardía M; Navarro-Ranninger C
    J Med Chem; 2002 Apr; 45(9):1835-44. PubMed ID: 11960495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. In vitro colony inhibition of carboplatin against stomach and lung cancer cell lines in comparison with cisplatin.
    Takahashi H; Sasaki Y; Saijo N; Sakurai M; Nakano H; Nakagawa K; Hoshi A; Jett JR; Hong WS
    Cancer Chemother Pharmacol; 1987; 19(3):197-200. PubMed ID: 3034444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effects of a new antioestrogen, idoxifene, on cisplatin- and doxorubicin-sensitive and -resistant human ovarian carcinoma cell lines.
    Sharp SY; Rowlands MG; Jarman M; Kelland LR
    Br J Cancer; 1994 Sep; 70(3):409-14. PubMed ID: 8080723
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
    Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
    Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Expression of p53 in cisplatin-resistant ovarian cancer cell lines: modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-platinum(IV).
    Hagopian GS; Mills GB; Khokhar AR; Bast RC; Siddik ZH
    Clin Cancer Res; 1999 Mar; 5(3):655-63. PubMed ID: 10100719
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
    Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
    Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Lack of a role for MRP1 in platinum drug resistance in human ovarian cancer cell lines.
    Sharp SY; Smith V; Hobbs S; Kelland LR
    Br J Cancer; 1998 Jul; 78(2):175-80. PubMed ID: 9683290
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
    Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
    Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Novel mechanisms of platinum drug resistance identified in cells selected for resistance to JM118 the active metabolite of satraplatin.
    Samimi G; Kishimoto S; Manorek G; Breaux JK; Howell SB
    Cancer Chemother Pharmacol; 2007 Feb; 59(3):301-12. PubMed ID: 16770583
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Potentiation of cisplatin and carboplatin cytotoxicity by amphotericin B in different human ovarian carcinoma and malignant peritoneal mesothelioma cells.
    Poulain L; Sichel F; Crouet H; Bureau F; Gauduchon P; Gignoux M; Le Talaër JY
    Cancer Chemother Pharmacol; 1997; 40(5):385-90. PubMed ID: 9272114
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development of resistance to a trinuclear platinum complex in ovarian carcinoma cells.
    Perego P; Gatti L; Righetti SC; Beretta GL; Carenini N; Corna E; Dal Bo L; Tinelli S; Colangelo D; Leone R; Apostoli P; Lombardi L; Beggiolin G; Piazzoni L; Zunino F
    Int J Cancer; 2003 Jul; 105(5):617-24. PubMed ID: 12740909
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Studies of interaction of trichloro{eta2-cis-N,N-dimethyl-1-[6-(N',N'-dimethyl-ammoniummethyl)-cyclohex-3-ene-1-yl]-methylammonium}platinum(II) chloride with DNA: Effects on secondary and tertiary structures of DNA. Cytotoxic assays on human ovarian cancer cell lines, resistant and non-resistant to cisplatin.
    Gay M; Montaña AM; Moreno V; Prieto MJ; Pérez JM; Alonso C
    Bioorg Med Chem; 2006 Mar; 14(5):1565-72. PubMed ID: 16256352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.